board is quiet

Quote
You are disregarding the fact that apligraft can also treat dlu and vlu. The plan was to ramp up aplgiraft and spend a few millions for reeducation purposes if the decision stands. As mentioned above, it will not completely offset the revenue loss but 50% of something is still better than 100% of nothing. The 50m was an estimate to adjust the internal forecast but it was not made clear if this included the increased revenue from aplgiraft. These were the assumptions when I was still at Oragno. Regarding the margin, this was directly from AX though I agree it's heavily skewed toward apligraft. This is because some of cost accounts hit apligraft directly instead of being allocated to other products.
 












Apligraf is expensive to make and not shelf stable. Increasing production is a huge logistical challenge as well. Layoffs gonna suck as many departments been gutted already
 












anonymous said:
Apligraf is expensive to make and not shelf stable. Increasing production is a huge logistical challenge as well. Layoffs gonna suck as many departments been gutted already
Click to expand...
This is true but they need to protect market share. It's not a logistics nightmare because they already manufacture apligraft in large quantity. The main challenge is the cost to ramp up staff which needs to be offset by reduction in other areas.
 






anonymous said:
This is true but they need to protect market share. It's not a logistics nightmare because they already manufacture apligraft in large quantity. The main challenge is the cost to ramp up staff which needs to be offset by reduction in other areas.
Click to expand...
This is assuming the market actually wants Apligraft. Its an old product.
 


















anonymous said:
This is assuming the market actually wants Apligraft. Its an old product.
Click to expand...
Apligraf and Dermagraft are great tried and proven products and have better efficacy than PP. The problem is the company didn't put a lot of effort pushing the transition to these products or work on increasing the production capacity. They have an opportunity to capture the market share, but considering how unorganized management is its going to be a sh*t show.
 






Apligraf production costs do not scale like other products do. Meaning, it doesn’t get any cheaper to make more. They don’t want to sell more bc as mentioned many times, the margin is half of what they make with PP or Cygnus. Aside from the products, take a look at the bigger picture.
Percent of total wounds treated with skin substitutes has remained constant for over a decade 2-3%. The number of wounds has grown due to demographics but not percent or penetration. Why do you think they went after Derm or repeatedly fail in Surgical? They’re looking for new markets.
Organo has not gained market share over the last 4 years, it’s just traded lower cost products for higher cost products. Without the ability to capture market share from the competition they are stuck with the same number of customers buying less expensive products. Check the numbers. Ask your friends in marketing or finance to tell you the number of accounts over the last 4 years. No one looks at the root cause when everyone is getting paid. Will there be layoffs? Check the history? What happens when someone up top makes a few booboos? Cut heads.
From planning, to strategy, to production, to incentive plan, to sales territory hiring, to distribution, to IT, there are massive mistakes across all these areas.
Will Orgo find a way to remake itself again? Given its history… probably.
Will there be layoffs? Given its history… Definitely.
Will Gary make millions of dollars continuing to make terrible decisions?
Absolutely.
 






In 2023, there were two rounds of layoffs, and I was affected by one of them. During my time there, I witnessed significant financial waste, which led to many high-performing, long-term employees being sacrificed to protect upper management. Consequently, numerous corporate departments were severely impacted. The decision to implement D365 from the beginning was flawed; superior alternatives like SAP were available. Although the intention was to save money with D365, it ultimately resulted in higher costs.
 






anonymous said:
In 2023, there were two rounds of layoffs, and I was affected by one of them. During my time there, I witnessed significant financial waste, which led to many high-performing, long-term employees being sacrificed to protect upper management. Consequently, numerous corporate departments were severely impacted. The decision to implement D365 from the beginning was flawed; superior alternatives like SAP were available. Although the intention was to save money with D365, it ultimately resulted in higher costs.
Click to expand...

Remember the customer portal that had been in the works for 5 years!

Or burn products

Or not having to fax BVs.

Or getting a functional CRM.
 






Organo is actually losing marketing share in its original segment, wound centers. They are being outworked and outmanned in the major national accounts. It’s a sorry bunch of rejects that are walking into the largest managers of wound centers.
 






anonymous said:
It’s a sorry bunch of rejects that are walking into the largest managers of wound centers.
Click to expand...
Nepotism undermines a company's success by prioritizing family ties over merit, leading to a less qualified workforce and lower morale. Talented employees who see favoritism in promotions or hiring are likely to feel undervalued and disengaged, often leaving for more fair and rewarding opportunities. This leads to stagnation, as top talent exits and the company struggles to attract skilled candidates. Ultimately, nepotism creates a toxic culture, breeds resentment, and hampers growth, leaving the organization vulnerable to long-term decline.
 


















anonymous said:
Nepotism undermines a company's success by prioritizing family ties over merit, leading to a less qualified workforce and lower morale. Talented employees who see favoritism in promotions or hiring are likely to feel undervalued and disengaged, often leaving for more fair and rewarding opportunities. This leads to stagnation, as top talent exits and the company struggles to attract skilled candidates. Ultimately, nepotism creates a toxic culture, breeds resentment, and hampers growth, leaving the organization vulnerable to long-term decline.
Click to expand...
It was once a great company that had respect and many clinicians supporting and wantting to be involved. What happened to this. Egos got in the way andd other companies took advantage of this.
 












anonymous said:
solely ego?
Click to expand...
yes and everything that goes with ego's. We cannot see the damage we have done with most customers. They do not like us and we are a target. Why did Kerecis get bought? We were in the mix and they selected them. Why? They see more with them than us. Look t our stock, this shows their is a lack of confidence in our company.
 






anonymous said:
yes and everything that goes with ego's. We cannot see the damage we have done with most customers. They do not like us and we are a target. Why did Kerecis get bought? We were in the mix and they selected them. Why? They see more with them than us. Look t our stock, this shows their is a lack of confidence in our company.
Click to expand...
What do you mean by damage? How did that happen?
 






Top Bottom
Back
Quote